Yu-Chuan Lin

This inventor holds 1 USPTO granted patent. Top assignee: China Medical University Hospital. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yu-Chuan Lin. Retrieved from https://idiyas.com/inventor/yu-chuan-lin-cxwko5li

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 1.0


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Yu-Chuan Lin: Innovator in Medical Biotechnology

Introduction

Yu-Chuan Lin is a prominent inventor in the field of medical biotechnology. He has made significant contributions through his innovative research and development efforts. His work focuses on advancing therapeutic techniques and improving patient outcomes.

Latest Patents

Yu-Chuan Lin holds a patent titled "Fusion Protein Comprising Anti-CD3 Single Domain Antibody, Exosomal Protein CD63 and RNA Binding Protein, and Uses Thereof." This patent represents a novel approach to enhancing immune responses and has potential applications in various medical treatments. He has 1 patent to his name.

Career Highlights

Yu-Chuan Lin is affiliated with China Medical University Hospital, where he conducts his research. His role at the hospital allows him to collaborate with other experts in the field and contribute to groundbreaking medical advancements. His dedication to improving healthcare through innovation is evident in his work.

Collaborations

Due to space constraints, the details of his collaborations will not be included.

Conclusion

Yu-Chuan Lin is a notable inventor whose work in medical biotechnology is paving the way for future innovations. His contributions are essential in the ongoing quest to enhance medical treatments and improve patient care.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…